Invention Grant
- Patent Title: Aziridinyl containing compounds and methods of inactivating nucleic acid molecules using the same
-
Application No.: US16213052Application Date: 2018-12-07
-
Publication No.: US10738005B2Publication Date: 2020-08-11
- Inventor: David R. Tabatadze
- Applicant: ZATA Pharmaceuticals, Inc
- Applicant Address: US MA Worcester
- Assignee: ZATA Pharmaceuticals, Inc.
- Current Assignee: ZATA Pharmaceuticals, Inc.
- Current Assignee Address: US MA Worcester
- Agency: Fox Rothschild LLP
- Main IPC: C07D203/12
- IPC: C07D203/12 ; A61L2/16

Abstract:
Described herein are compositions and compounds having one or more aziridinyl groups, and methods of making the same. The compounds can also have one or more nitrogen atoms that each can be positively charged. The composition and compounds can inactivate one or more nucleic acid molecules (e.g. a DNA and/or a RNA from a pathogen) in a sample. The sample can comprise a blood or blood product (e.g., donated blood). The compositions and compounds can inactivate any nucleic acid present in a blood or blood product, thereby making the blood or blood product safe for use (e.g., in a transfusion).
Public/Granted literature
- US20190106386A1 AZIRIDINYL CONTAINING COMPOUNDS AND METHODS OF INACTIVATING NUCLEIC ACID MOLECULES USING THE SAME Public/Granted day:2019-04-11
Information query